← All trials
NCT06699459
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 14, 2024
- Primary completion
- Nov 15, 2026
- Completion date
- Nov 15, 2026
- First posted
- Nov 21, 2024
- Last posted
- Nov 21, 2024
- Enrollment
- 76
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zhejiang UniversityLead sponsor
- Shaoxing People's HospitalCollaborator
- Zhejiang UniversityOfficial
- Fujian Provincial HospitalCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Ningbo No. 1 HospitalCollaborator
- Southern Medical UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Jiao Tong UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.